Barclays
SMTI icon

Barclays’s Sanara MedTech SMTI Stock Holding History

Barclays’s Portfolio SMTI Stock Details SMTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$36.2K Sell
2,105
-4,201
-67% -$86.4K ﹤0.01% 4423
2025
Q4 		$147K Sell
6,306
-1,444
-19% -$37.3K ﹤0.01% 4463
2025
Q3 		$246K Sell
7,750
-1,103
-12% -$33.3K ﹤0.01% 4201
2025
Q2 		$251K Buy
8,853
+4,442
+101% +$133K ﹤0.01% 4138
2025
Q1 		$136K Sell
4,411
-2,012
-31% -$68.3K ﹤0.01% 4282
2024
Q4 		$213K Buy
6,423
+692
+12% +$23.5K ﹤0.01% 4278
2024
Q3 		$173K Buy
5,731
+4,376
+323% +$136K ﹤0.01% 4365
2024
Q2 		$38.2K Sell
1,355
-1,344
-50% -$42.2K ﹤0.01% 4305
2024
Q1 		$99.9K Sell
2,699
-2,637
-49% -$98.6K ﹤0.01% 4438
2023
Q4 		$219K Buy
5,336
+4,653
+681% +$149K ﹤0.01% 4376
2023
Q3 		$21.3K Sell
683
-74
-10% -$2.87K ﹤0.01% 4166
2023
Q2 		$30.4K Buy
+757
New +$31K ﹤0.01% 4034

Other funds holding SMTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SWM
Stonebridge Wealth Management Oak Brook, Illinois $112M AUM 23.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Barclays's SMTI Position: Q1 2026 in Review

Barclays reduced its Sanara MedTech (SMTI) stake by 67% in Q1 2026, selling an estimated $86.4K and leaving 2,105 shares worth $36.2K. The position accounts for ﹤0.01% of the portfolio, ranked #4423.

Barclays first reported a position in SMTI in Q2 2023 and has held it in 12 quarters since. The position peaked at $251K in Q2 2025. 65 funds tracked by Wall St. Rank hold SMTI as of Q1 2026.

  • Barclays held 2,105 shares of Sanara MedTech worth $36.2K as of Q1 2026.
  • Barclays sold 4,201 Sanara MedTech shares in Q1 2026, an estimated $86.4K.
  • Sanara MedTech made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4423 holding.
  • Barclays first reported a position in Sanara MedTech in Q2 2023 and has held it in 12 quarters since.
  • Barclays's Sanara MedTech position peaked at $251K in Q2 2025.
  • 65 funds tracked by Wall St. Rank held Sanara MedTech as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.